123 Imaging in the follow-up of differentiated thyroid cancer [7]

Clinical Oncology

Volumn 13, Issue 4, 2001, Pages 314-

  Fenwick, J D ^a   Mallick, U K ^a   Perros, P ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 123; IODINE 131; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

CANCER GRADING; DIAGNOSTIC IMAGING; DRUG HALF LIFE; DRUG PURITY; FOLLOW UP; HUMAN; LETTER; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; RADIATION EXPOSURE; SENSITIVITY AND SPECIFICITY; THYROID CANCER; THYROIDECTOMY; WHOLE BODY SCINTISCANNING; NOTE; SCINTISCANNING; THYROID TUMOR;

HUMANS; IODINE RADIOISOTOPES; THYROID NEOPLASMS;

EID: 0034859755     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Radioiodine treatment for differentiated thyroid cancer
2. Northern Cancer Network guidelines for management of thyroid cancer
3. ICRP Radiation dose to patients from radiopharmaceuticals
4. 123-I diagnostic scanning in the follow-up of patients with differentiated thyroid cancer; avoidance of negative uptake of therapeutic radio iodine to 'stunning'
5. An analysis of 'ablation of thyroid remnants' with I-131 in 511 patients from 1947-1984: Experience at University of Michigan